-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Simufilam Hydrochloride in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Simufilam Hydrochloride in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Simufilam Hydrochloride in Dementia Associated With Alzheimer's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Quemliclustat in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quemliclustat in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Quemliclustat in Pancreatic Ductal Adenocarcinoma Drug Details: Quemliclustat is under...
-
Company Insights
NewMarsh – Tech Innovator Profile
This report provides insight into Marsh, including an overview of the company, coverage of its business model and operations, and biographies of its senior management. Marsh (a subsidiary of Marsh & McLennan Companies) is an insurance broking and risk management company. It serves both individual and commercial clients with data-enabled risk solutions and advisory services. The company’s key offerings include data, analytics, and technology services; captive insurance expertise; casualty insurance services; claims expertise; flood insurance expertise and services; terrorism risk...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Metastatic Pancreatic Cancer Drug Details: ALG.APV-527 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EMB-07 in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EMB-07 in Metastatic Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EMB-07 in Metastatic Prostate Cancer Drug Details: EMB-07 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EMB-07 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EMB-07 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EMB-07 in Triple-Negative Breast Cancer (TNBC) Drug Details: EMB-07...
-
Sector Analysis
Oman Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Oman Defense Market Report Overview The Oman defense budget is $8 billion in 2024. The country’s defense budget will grow at a CAGR of more than 2% during 2025-2029. This can be attributed to the rising arms race in the region to intercept the growing turbulence in neighboring countries such as Syria and Yemen. In addition, the increase in oil prices will facilitate increases in Oman's defense budget. Oman Defense Market Outlook, 2024-2029 ($ Billion) Buy the Full Report for...
-
Sector Analysis
Albania Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Albania Defense Market Report Overview The Albania defense budget is valued at $346.5 million and is expected to grow at a CAGR of more than 7% during 2025-2029. The Russian invasion of Ukraine has spurred the country’s defense budget like many other European nations. Albania Defense Market Outlook, 2024-2029 ($ Million) Buy the Full Report for More Insights into the Albania Defense Market Forecast Download a Free Report Sample The Albania defense market research report provides the market size forecast...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belrestotug in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belrestotug in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belrestotug in Refractory Multiple Myeloma Drug Details: EOS-448 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC) Drug Details:...